Research ArticleArticle
Open Access
Effectiveness of Rituximab for the Treatment of Rheumatoid Arthritis in Patients with Prior Exposure to Anti-TNF: Results from the CORRONA Registry
Leslie R. Harrold, George W. Reed, Ashwini Shewade, Robert Magner, Katherine C. Saunders, Ani John, Joel M. Kremer and Jeffrey D. Greenberg
The Journal of Rheumatology May 2015, jrheum.141043; DOI: https://doi.org/10.3899/jrheum.141043
Leslie R. Harrold
From the University of Massachusetts Medical School, Worcester; Corrona LLC, Southborough, Massachusetts; Genentech Inc., South San Francisco, California; Albany Medical College and The Center for Rheumatology, Albany; New York University (NYU) School of Medicine, New York, New York, USA. The CORRONA Rheumatoid Arthritis registry has been supported through contracted subscriptions in the last 2 years by Abbvie, Amgen, AstraZeneca, Genentech, Horizon Pharma, Eli Lilly, Novartis, Pfizer, Vertex, and UCB. Support for third-party writing assistance for this manuscript, furnished by Vivian Chen, PharmD, and Eric Deutsch, PhD of Health Interactions, was provided by F. Hoffmann-La Roche Ltd. L.R. Harrold, MD, MPH, Department of Medicine, University of Massachusetts Medical School; G.W. Reed, PhD, Department of Medicine, University of Massachusetts Medical School, and Corrona LLC; A. Shewade, MS, Genentech Inc.; R. Magner, MPH, Department of Medicine, University of Massachusetts Medical School; K.C. Saunders, MS, Corrona LLC; A. John, BSN, MPH, Genentech Inc.; J.M. Kremer, MD, Department of Rheumatology, Albany Medical College, and The Center for Rheumatology; J.D. Greenberg, MD, MPH, Department of Medicine, Division of Rheumatology, NYU School of Medicine. Address correspondence to Associate Professor L.R. Harrold, University of Massachusetts Medical School, 55 Lake Ave. North, Worcester, Massachusetts 01655, USA. E-mail: Leslie.Harrold@umassmed.edu Full Release Article. For details see Reprints/Permissions at jrheum.com. Accepted for publication March 10, 2015.
George W. Reed
From the University of Massachusetts Medical School, Worcester; Corrona LLC, Southborough, Massachusetts; Genentech Inc., South San Francisco, California; Albany Medical College and The Center for Rheumatology, Albany; New York University (NYU) School of Medicine, New York, New York, USA. The CORRONA Rheumatoid Arthritis registry has been supported through contracted subscriptions in the last 2 years by Abbvie, Amgen, AstraZeneca, Genentech, Horizon Pharma, Eli Lilly, Novartis, Pfizer, Vertex, and UCB. Support for third-party writing assistance for this manuscript, furnished by Vivian Chen, PharmD, and Eric Deutsch, PhD of Health Interactions, was provided by F. Hoffmann-La Roche Ltd. L.R. Harrold, MD, MPH, Department of Medicine, University of Massachusetts Medical School; G.W. Reed, PhD, Department of Medicine, University of Massachusetts Medical School, and Corrona LLC; A. Shewade, MS, Genentech Inc.; R. Magner, MPH, Department of Medicine, University of Massachusetts Medical School; K.C. Saunders, MS, Corrona LLC; A. John, BSN, MPH, Genentech Inc.; J.M. Kremer, MD, Department of Rheumatology, Albany Medical College, and The Center for Rheumatology; J.D. Greenberg, MD, MPH, Department of Medicine, Division of Rheumatology, NYU School of Medicine. Address correspondence to Associate Professor L.R. Harrold, University of Massachusetts Medical School, 55 Lake Ave. North, Worcester, Massachusetts 01655, USA. E-mail: Leslie.Harrold@umassmed.edu Full Release Article. For details see Reprints/Permissions at jrheum.com. Accepted for publication March 10, 2015.
Ashwini Shewade
From the University of Massachusetts Medical School, Worcester; Corrona LLC, Southborough, Massachusetts; Genentech Inc., South San Francisco, California; Albany Medical College and The Center for Rheumatology, Albany; New York University (NYU) School of Medicine, New York, New York, USA. The CORRONA Rheumatoid Arthritis registry has been supported through contracted subscriptions in the last 2 years by Abbvie, Amgen, AstraZeneca, Genentech, Horizon Pharma, Eli Lilly, Novartis, Pfizer, Vertex, and UCB. Support for third-party writing assistance for this manuscript, furnished by Vivian Chen, PharmD, and Eric Deutsch, PhD of Health Interactions, was provided by F. Hoffmann-La Roche Ltd. L.R. Harrold, MD, MPH, Department of Medicine, University of Massachusetts Medical School; G.W. Reed, PhD, Department of Medicine, University of Massachusetts Medical School, and Corrona LLC; A. Shewade, MS, Genentech Inc.; R. Magner, MPH, Department of Medicine, University of Massachusetts Medical School; K.C. Saunders, MS, Corrona LLC; A. John, BSN, MPH, Genentech Inc.; J.M. Kremer, MD, Department of Rheumatology, Albany Medical College, and The Center for Rheumatology; J.D. Greenberg, MD, MPH, Department of Medicine, Division of Rheumatology, NYU School of Medicine. Address correspondence to Associate Professor L.R. Harrold, University of Massachusetts Medical School, 55 Lake Ave. North, Worcester, Massachusetts 01655, USA. E-mail: Leslie.Harrold@umassmed.edu Full Release Article. For details see Reprints/Permissions at jrheum.com. Accepted for publication March 10, 2015.
Robert Magner
From the University of Massachusetts Medical School, Worcester; Corrona LLC, Southborough, Massachusetts; Genentech Inc., South San Francisco, California; Albany Medical College and The Center for Rheumatology, Albany; New York University (NYU) School of Medicine, New York, New York, USA. The CORRONA Rheumatoid Arthritis registry has been supported through contracted subscriptions in the last 2 years by Abbvie, Amgen, AstraZeneca, Genentech, Horizon Pharma, Eli Lilly, Novartis, Pfizer, Vertex, and UCB. Support for third-party writing assistance for this manuscript, furnished by Vivian Chen, PharmD, and Eric Deutsch, PhD of Health Interactions, was provided by F. Hoffmann-La Roche Ltd. L.R. Harrold, MD, MPH, Department of Medicine, University of Massachusetts Medical School; G.W. Reed, PhD, Department of Medicine, University of Massachusetts Medical School, and Corrona LLC; A. Shewade, MS, Genentech Inc.; R. Magner, MPH, Department of Medicine, University of Massachusetts Medical School; K.C. Saunders, MS, Corrona LLC; A. John, BSN, MPH, Genentech Inc.; J.M. Kremer, MD, Department of Rheumatology, Albany Medical College, and The Center for Rheumatology; J.D. Greenberg, MD, MPH, Department of Medicine, Division of Rheumatology, NYU School of Medicine. Address correspondence to Associate Professor L.R. Harrold, University of Massachusetts Medical School, 55 Lake Ave. North, Worcester, Massachusetts 01655, USA. E-mail: Leslie.Harrold@umassmed.edu Full Release Article. For details see Reprints/Permissions at jrheum.com. Accepted for publication March 10, 2015.
Katherine C. Saunders
From the University of Massachusetts Medical School, Worcester; Corrona LLC, Southborough, Massachusetts; Genentech Inc., South San Francisco, California; Albany Medical College and The Center for Rheumatology, Albany; New York University (NYU) School of Medicine, New York, New York, USA. The CORRONA Rheumatoid Arthritis registry has been supported through contracted subscriptions in the last 2 years by Abbvie, Amgen, AstraZeneca, Genentech, Horizon Pharma, Eli Lilly, Novartis, Pfizer, Vertex, and UCB. Support for third-party writing assistance for this manuscript, furnished by Vivian Chen, PharmD, and Eric Deutsch, PhD of Health Interactions, was provided by F. Hoffmann-La Roche Ltd. L.R. Harrold, MD, MPH, Department of Medicine, University of Massachusetts Medical School; G.W. Reed, PhD, Department of Medicine, University of Massachusetts Medical School, and Corrona LLC; A. Shewade, MS, Genentech Inc.; R. Magner, MPH, Department of Medicine, University of Massachusetts Medical School; K.C. Saunders, MS, Corrona LLC; A. John, BSN, MPH, Genentech Inc.; J.M. Kremer, MD, Department of Rheumatology, Albany Medical College, and The Center for Rheumatology; J.D. Greenberg, MD, MPH, Department of Medicine, Division of Rheumatology, NYU School of Medicine. Address correspondence to Associate Professor L.R. Harrold, University of Massachusetts Medical School, 55 Lake Ave. North, Worcester, Massachusetts 01655, USA. E-mail: Leslie.Harrold@umassmed.edu Full Release Article. For details see Reprints/Permissions at jrheum.com. Accepted for publication March 10, 2015.
Ani John
From the University of Massachusetts Medical School, Worcester; Corrona LLC, Southborough, Massachusetts; Genentech Inc., South San Francisco, California; Albany Medical College and The Center for Rheumatology, Albany; New York University (NYU) School of Medicine, New York, New York, USA. The CORRONA Rheumatoid Arthritis registry has been supported through contracted subscriptions in the last 2 years by Abbvie, Amgen, AstraZeneca, Genentech, Horizon Pharma, Eli Lilly, Novartis, Pfizer, Vertex, and UCB. Support for third-party writing assistance for this manuscript, furnished by Vivian Chen, PharmD, and Eric Deutsch, PhD of Health Interactions, was provided by F. Hoffmann-La Roche Ltd. L.R. Harrold, MD, MPH, Department of Medicine, University of Massachusetts Medical School; G.W. Reed, PhD, Department of Medicine, University of Massachusetts Medical School, and Corrona LLC; A. Shewade, MS, Genentech Inc.; R. Magner, MPH, Department of Medicine, University of Massachusetts Medical School; K.C. Saunders, MS, Corrona LLC; A. John, BSN, MPH, Genentech Inc.; J.M. Kremer, MD, Department of Rheumatology, Albany Medical College, and The Center for Rheumatology; J.D. Greenberg, MD, MPH, Department of Medicine, Division of Rheumatology, NYU School of Medicine. Address correspondence to Associate Professor L.R. Harrold, University of Massachusetts Medical School, 55 Lake Ave. North, Worcester, Massachusetts 01655, USA. E-mail: Leslie.Harrold@umassmed.edu Full Release Article. For details see Reprints/Permissions at jrheum.com. Accepted for publication March 10, 2015.
Joel M. Kremer
From the University of Massachusetts Medical School, Worcester; Corrona LLC, Southborough, Massachusetts; Genentech Inc., South San Francisco, California; Albany Medical College and The Center for Rheumatology, Albany; New York University (NYU) School of Medicine, New York, New York, USA. The CORRONA Rheumatoid Arthritis registry has been supported through contracted subscriptions in the last 2 years by Abbvie, Amgen, AstraZeneca, Genentech, Horizon Pharma, Eli Lilly, Novartis, Pfizer, Vertex, and UCB. Support for third-party writing assistance for this manuscript, furnished by Vivian Chen, PharmD, and Eric Deutsch, PhD of Health Interactions, was provided by F. Hoffmann-La Roche Ltd. L.R. Harrold, MD, MPH, Department of Medicine, University of Massachusetts Medical School; G.W. Reed, PhD, Department of Medicine, University of Massachusetts Medical School, and Corrona LLC; A. Shewade, MS, Genentech Inc.; R. Magner, MPH, Department of Medicine, University of Massachusetts Medical School; K.C. Saunders, MS, Corrona LLC; A. John, BSN, MPH, Genentech Inc.; J.M. Kremer, MD, Department of Rheumatology, Albany Medical College, and The Center for Rheumatology; J.D. Greenberg, MD, MPH, Department of Medicine, Division of Rheumatology, NYU School of Medicine. Address correspondence to Associate Professor L.R. Harrold, University of Massachusetts Medical School, 55 Lake Ave. North, Worcester, Massachusetts 01655, USA. E-mail: Leslie.Harrold@umassmed.edu Full Release Article. For details see Reprints/Permissions at jrheum.com. Accepted for publication March 10, 2015.
Jeffrey D. Greenberg
From the University of Massachusetts Medical School, Worcester; Corrona LLC, Southborough, Massachusetts; Genentech Inc., South San Francisco, California; Albany Medical College and The Center for Rheumatology, Albany; New York University (NYU) School of Medicine, New York, New York, USA. The CORRONA Rheumatoid Arthritis registry has been supported through contracted subscriptions in the last 2 years by Abbvie, Amgen, AstraZeneca, Genentech, Horizon Pharma, Eli Lilly, Novartis, Pfizer, Vertex, and UCB. Support for third-party writing assistance for this manuscript, furnished by Vivian Chen, PharmD, and Eric Deutsch, PhD of Health Interactions, was provided by F. Hoffmann-La Roche Ltd. L.R. Harrold, MD, MPH, Department of Medicine, University of Massachusetts Medical School; G.W. Reed, PhD, Department of Medicine, University of Massachusetts Medical School, and Corrona LLC; A. Shewade, MS, Genentech Inc.; R. Magner, MPH, Department of Medicine, University of Massachusetts Medical School; K.C. Saunders, MS, Corrona LLC; A. John, BSN, MPH, Genentech Inc.; J.M. Kremer, MD, Department of Rheumatology, Albany Medical College, and The Center for Rheumatology; J.D. Greenberg, MD, MPH, Department of Medicine, Division of Rheumatology, NYU School of Medicine. Address correspondence to Associate Professor L.R. Harrold, University of Massachusetts Medical School, 55 Lake Ave. North, Worcester, Massachusetts 01655, USA. E-mail: Leslie.Harrold@umassmed.edu Full Release Article. For details see Reprints/Permissions at jrheum.com. Accepted for publication March 10, 2015.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Effectiveness of Rituximab for the Treatment of Rheumatoid Arthritis in Patients with Prior Exposure to Anti-TNF: Results from the CORRONA Registry
Leslie R. Harrold, George W. Reed, Ashwini Shewade, Robert Magner, Katherine C. Saunders, Ani John, Joel M. Kremer, Jeffrey D. Greenberg
The Journal of Rheumatology May 2015, jrheum.141043; DOI: 10.3899/jrheum.141043
Effectiveness of Rituximab for the Treatment of Rheumatoid Arthritis in Patients with Prior Exposure to Anti-TNF: Results from the CORRONA Registry
Leslie R. Harrold, George W. Reed, Ashwini Shewade, Robert Magner, Katherine C. Saunders, Ani John, Joel M. Kremer, Jeffrey D. Greenberg
The Journal of Rheumatology May 2015, jrheum.141043; DOI: 10.3899/jrheum.141043